Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10896688 | PMC |
| http://dx.doi.org/10.14701/ahbps.28-1_C | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Directed differentiation of human pluripotent stem cells into pancreatobiliary co-progenitor-like population.
Biochem Biophys Res Commun
August 2025
Department of Developmental and Regenerative Biology, iORGANtech Limited Company (Suzhou), Suzhou, 215000, China; Tianjin Key Laboratory of Early Druggability Evaluation of Innovative Drugs and Tianjin Key Laboratory of Molecular Drug Research, Tianjin International Joint Academy of Biomedicine, Tia
Progress in uncovering the causes of extrahepatic biliary diseases and developing new therapies has been constrained by the inaccessibility of donor tissue and a lack of experimental models. Although hepatic, intrahepatic biliary, and pancreatic 2D/3D models have been successfully established from pluripotent stem cells (PSCs), in vitro generation of extrahepatic biliary cells remains a major challenge, due to the absence of developmental cues. Here we report a de novo method for directed differentiation of human PSCs (both embryonic and induced) into pancreato-biliary progenitors-like cells (PBPLCs).
View Article and Find Full Text PDFModified Endoscopic Biliary Stent Combined with Photodynamic Therapy: A New Strategy for the Palliative Treatment of Extrahepatic Cholangiocarcinoma.
Photobiomodul Photomed Laser Surg
September 2025
Department of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Photodynamic therapy (PDT) combined with biliary stenting reportedly has better efficacy and safety in the treatment of extrahepatic cholangiocarcinoma (EHC). Considering the shortcomings of traditional PDT methods, we proposed a novel modified approach, defined as initial biliary stent placement followed by PDT, for the treatment of EHC. The study aimed to evaluate the effect and safety of biliary stent placement prior to PDT versus only stent placement on the treatment of EHC.
View Article and Find Full Text PDFEfficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma: survival outcomes and prognostic factors from a systematic review and meta-analysis.
Hepatobiliary Surg Nutr
August 2025
Division of Biliary Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China.
Background: Advanced hepatocellular carcinoma (HCC) poses significant treatment challenges, with limited options and poor prognosis. Hepatic arterial infusion chemotherapy (HAIC) has emerged as a promising therapy, potentially offering superior outcomes compared to transarterial chemoembolization (TACE). This study aimed to systematically compare the survival outcomes and safety profiles of HAIC versus TACE in patients with advanced HCC, and to identify key prognostic factors influencing treatment efficacy to guide personalized therapeutic strategies.
View Article and Find Full Text PDFCorrelation of Spleen Stiffness with Esophageo-gastric Variceal Bleeding in Patients with Non-cirrhotic Portal Hypertension.
Dig Dis Sci
September 2025
Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, 110070, India.
Background: Bleeding from esophageo-gastric varices is a serious complication related to portal hypertension. In patients with cirrhosis, liver and splenic stiffness measurements (LSM and SSM) are useful to predict high-risk varices, bleeding and decompensation. Data regarding the utility of SSM for predicting bleeding in patients with non-cirrhotic portal hypertension (NCPH) is scarce.
View Article and Find Full Text PDFRevisiting the role of local treatments in the era of targeted therapy and immunotherapy for hepatocellular carcinoma.
World J Surg Oncol
August 2025
Hepatic Surgery Center, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
The advent of targeted therapy and immunotherapy has revolutionised the management of hepatocellular carcinoma (HCC) patients with all stages, dramatically improving their survival outcomes. Currently, radical resection is still the preferred first-line treatment for early-stage HCC, nevertheless, the surgical outcomes remain unsatisfactory due to high recurrence rate of 70% within 5 years after surgery. Moreover, up to two thirds of diagnosed HCC patients are in the advanced stages of the disease, exhibiting intrahepatic or extrahepatic metastases and vascular invasion.
View Article and Find Full Text PDF